Researchers are excited about this new drug, a innovative dual agonist showing remarkable results in early trials for size loss . It functions by targeting both systems: GLP-1 and GIP, these, when stimulated, support control cravings and improve energy expenditure . Preliminary observations indicate noteworthy size management and possible advantage